Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 3/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | USP14 | P54578 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549918 | 1.00 | NPC1 (0.37) | NPC1POLBRAB9ACYSLTR1PPARG | |
| SCHEMBL4014531 | 0.89 | NPC1 (0.33) | NPC1POLBRAB9ACYSLTR1BACE1 | |
| SCHEMBL31601511 | 0.86 | PPARG (0.34) | PPARGRXRA | |
| SCHEMBL23554539 | 0.84 | PREP (0.35) | NPC1POLBRAB9ARXRAGRIN1 | |
| SCHEMBL20757569 | 0.84 | DRD2 (0.33) | DRD2 | |
| SCHEMBL24247636 | 0.84 | — | — | |
| SCHEMBL29185149 | 0.81 | ESR1 (0.44) | BACE1 | |
| SCHEMBL3178345 | 0.81 | PPARG (0.40) | POLBPPARGPPARABACE1USP14 | |
| SCHEMBL31628296 | 0.81 | SMN1; SMN2 (0.41) | NPC1RAB9AFYN | |
| SCHEMBL5728406 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-4079734-B1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMR BIOTECHNOLOGY CO LTD (CN) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024173646-A1 | CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| CN-114302886-B | Triazolopyridazine derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2022-12-08 | — | — | US | disclosed |
| EP-4079734-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2022-10-26 | — | — | EP | disclosed |
| CN-106458995-A | 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicine containing same | 日本医事物理股份有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20100216758-A1 | Pyridone Compounds | MSD K.K. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-1916239-A1 | PYRIDONE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-30 | — | — | EP | disclosed |
| EP-0891415-A1 | CLEANING AGENT WITH OLIGOAMMINE ACTIVATOR COMPLEXES FOR PEROXIDE COMPOUNDS | Henkel Kommanditgesellschaft auf Aktien (DE) | 1999-01-20 | — | — | EP | disclosed |
| US-5821255-A | REGULATING THE SECRETION OF CORTICOTROPIN, BETA-ENDORPHIN OR PEPTIDES DERIVED FROM PROOPIOMELANOCORTIN | SANOFI (FR) | 1998-10-13 | — | — | US | disclosed |
| EP-0659747-B1 | Branched aminothiazole derivatives process for their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997036986-A1 | CLEANING AGENT WITH OLIGOAMMINE ACTIVATOR COMPLEXES FOR PEROXIDE COMPOUNDS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1997-10-09 | — | — | WO | disclosed |
| US-5602132-A | USEFUL IN TREATMENT OF PATHOLOGIES INVOLVING CORTICOTROPIN RELEASING FACTOR | SANOFI (FR) | 1997-02-11 | — | — | US | disclosed |
| CN-1127252-A | Branched-amino-sbustituted thiazoles, processes for their preparation and the pharmaceutical compositions which contain them | SANOFI SA (FR) | 1996-07-24 | — | — | CN | disclosed |
| EP-0659747-A1 | Branched aminothiazole derivatives process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1995-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | ABCG2, CYP4F8, CYP3A5 | NPC1 1320/4885POLB 3160/4885RAB9A 4055/4885 |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | NPC1 3706/4885POLB 4147/4885RAB9A 3694/4885 |
| US-20100216758-A1 | Pyridone Compounds | NPY1R, MC5R, MC1R | NPC1 3941/4885POLB 3709/4885RAB9A 4085/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | NPC1 357/4885POLB 3951/4885RAB9A 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.